Form 4: Oric Director Sells Shares Under 10b5-1 Plan

Oric Pharmaceuticals Director Richard A. Heyman sold 6,700 shares of common stock for approximately $80,430 through a pre-arranged 10b5-1 trading plan.

Summary

• Richard A. Heyman, a Director of Oric Pharmaceuticals, Inc., sold a total of 6,700 shares of common stock.
• The sales occurred on January 16, 2026, at a weighted average price of $12.0046 per share.
• The total value of the shares sold is approximately $80,430.22.
• The transactions were executed under a Rule 10b5-1 trading plan adopted by Mr. Heyman and RAHD Capital, LLC.
• Following these sales, Mr. Heyman beneficially owns 41,800 shares directly and 213,072 shares indirectly through RAHD Capital, LLC.

Sentiment

Score: 5

Explanation: The sale of shares by a director is generally a neutral event when conducted under a pre-arranged 10b5-1 plan, as it reflects personal financial planning rather than a change in outlook on the company's prospects.

Positives

• The sales were conducted under a Rule 10b5-1 trading plan, indicating pre-scheduled transactions rather than a reaction to recent company news.

Negatives

• A director selling shares reduces their direct stake in the company, which can sometimes be perceived negatively by investors.

Future Outlook

N/A

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends. It is specific to the director's personal stock holdings and trading plan.

Related Party Transactions

• Richard A. Heyman has voting and investment power over shares held by RAHD Capital, LLC, which is involved in the 10b5-1 trading plan.

Stakeholder Impact

• Shareholders may observe a slight reduction in direct insider ownership, though the 10b5-1 plan mitigates concerns about the timing of the sale.

Key Dates

Recommendation

The reported transaction is an insider sale executed under a pre-arranged 10b5-1 trading plan. Such sales are typically for personal financial management and do not necessarily signal a change in the company's fundamentals or future prospects. Therefore, this specific filing alone does not warrant a change in investment recommendation, suggesting a 'hold' position for existing investors.

Keywords

Oric Pharmaceuticals, ORIC, Insider Trading, Form 4, Richard A. Heyman, Stock Sale, 10b5-1 Plan, Director Transaction